Russell Frank Company’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Russell Frank Company’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$3.62M	Buy	329,495 +178,024	+118%	+$1.58M	0.01%	1526
2015 Q4	$1.39M	Sell	151,471 -254,085	-63%	-$2.13M	﹤0.01%	2052
2015 Q3	$2.81M	Buy	405,556 +233,663	+136%	+$2M	0.01%	1645
2015 Q2	$1.69M	Sell	171,893 -22,235	-11%	-$203K	﹤0.01%	2065
2015 Q1	$1.72M	Sell	194,128 -238,294	-55%	-$1.9M	﹤0.01%	1859
2014 Q4	$3.79M	Buy	432,422 +178,388	+70%	+$1.44M	0.01%	1462
2014 Q3	$1.75M	Buy	254,034 +149,060	+142%	+$893K	﹤0.01%	1807
2014 Q2	$505K	Hold	104,974	–	–	﹤0.01%	2319
2014 Q1	$478K	Sell	104,974 -5,263	-5%	-$25.4K	﹤0.01%	2401
2013 Q4	$525K	Sell	110,237 -54,126	-33%	-$260K	﹤0.01%	2335
2013 Q3	$855K	Buy	164,363 +145,397	+767%	+$810K	﹤0.01%	2252
2013 Q2	$94K	Buy	+18,966	New	+$90.3K	﹤0.01%	2757

Other funds holding SCLN

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's SCLN Position: Q1 2016 in Review

Russell Frank Company increased its Sciclone Pharmaceuticals Inc (SCLN) stake by 118% in Q1 2016, buying an estimated $1.58M and bringing the position to 329,495 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #1526.

Russell Frank Company first reported a position in SCLN in Q2 2013 and has held it in 12 quarters since. The position peaked at $3.79M in Q4 2014. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

Russell Frank Company held 329,495 shares of Sciclone Pharmaceuticals Inc worth $3.62M as of Q1 2016.
Russell Frank Company bought 178,024 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $1.58M.
Sciclone Pharmaceuticals Inc made up 0.01% of Russell Frank Company's portfolio in Q1 2016, its #1526 holding.
Russell Frank Company first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Sciclone Pharmaceuticals Inc position peaked at $3.79M in Q4 2014.
142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.